Testing a new sarbecovirus vaccine in healthy adults
Treatments studied
Part of Infections clinical trials.
This study tests a new vaccine called GBP511, designed to protect against several types of sarbecoviruses (including COVID-19). It is for healthy adults who have already received a primary COVID-19 vaccine series plus at least one booster, at least 24 weeks before joining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old (for the first stage) or 18 and older (for the second stage).
- You are generally healthy, as confirmed by a medical check-up.
- You have had a primary COVID-19 vaccine series and at least one booster shot, and it has been at least 24 weeks since that booster.
- Your body mass index (BMI) is between 18.5 and 32.
- You agree to use effective birth control (if applicable) from 4 weeks before the first shot until 12 weeks after the last shot.
- You have no known history of COVID-19 infection in the past 24 weeks or any other serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental COVID-19 vaccine to see if it is safe and how well it works against current variants. It is for healthy adults who have had a previous COVID-19 vaccine or infection.
This trial tests a new COVID-19 vaccine called VYD2311, alone or with another COVID-19 vaccine, in healthy adults. The goal is to see if it is safe and helps your body fight the virus.
This trial tests a new medicine called HS-20152 in healthy people to see if it is safe and how the body handles it. Participants will receive vaccinations before the study to protect against certain infections.
This trial tests a new RSV vaccine in two phases. First, it will be given to healthy adults 18 and older to check safety. Then, it will be studied in adults 50 and older, including those with stable health conditions, to see if it helps protect against RSV, a common virus that can cause serious breathing problems in older people.
This trial tests a new medicine to see how the body handles it and whether it is safe. It is for healthy people, not for treating a disease, and helps researchers decide if the drug can move to the next stage of testing.
This study tests a single dose of a new medication called SYH2061 to see if it is safe and how the body processes it. It is for healthy adults aged 18 to 55 who have had certain vaccines and are willing to follow study rules.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.